CMS Needs Advisory Committees To Guide Coverage Decisions – Gottlieb
CMS should use an advisory committee process similar to FDA's to gain transparency and clinical expertise for making Medicare coverage decisions, American Enterprise Institute Resident Fellow Scott Gottlieb recommended at a recent Food & Drug Law Institute conference
You may also be interested in...
CMS' reasons for selecting topics for a possible national coverage determination are sometimes unclear and even inconsistent with the agency's own guidance, the two major drug and biologic manufacturer associations are telling the agency
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.